Karen Jean Ferrante's most recent trade in Cogent Biosciences Inc was a trade of 3,314 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 3,314 | 3,314 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 44,700 | 44,700 | - | - | Stock Option (Right to Buy) | |
| Macrogenics Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| Macrogenics Inc | Karen Jean Ferrante | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2025 | 6,500 | 0 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Karen Jean Ferrante | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2025 | 6,500 | 11,000 (0%) | 0% | - | Common Stock | |
| Macrogenics Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 3,750 | 3,750 | - | - | Restricted Stock Unit | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 3,788 | 3,788 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 2,785 | 2,785 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 2,034 | 2,034 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 2,462 | 2,462 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 44,700 | 44,700 | - | - | Stock Option (Right to Buy) | |
| Macrogenics Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 16,500 | 16,500 | - | - | Stock Option (right to buy) | |
| Macrogenics Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 6,500 | 6,500 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Karen Jean Ferrante | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 4,500 | 4,500 (0%) | 0% | 0 | Common Stock | |
| Macrogenics Inc | Karen Jean Ferrante | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 4,500 | 0 | - | - | Restricted Stock Unit | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 3,213 | 3,213 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Jean Karen Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 3,298 | 3,298 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 1,884 | 1,884 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 36,700 | 36,700 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 2,053 | 2,053 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 1,862 | 1,862 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 1,474 | 1,474 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 2,279 | 2,279 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 30,700 | 30,700 | - | - | Stock Option (Right to Buy) | |
| Macrogenics Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 20,640 | 20,640 | - | - | Stock Option (right to buy) | |
| Macrogenics Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 18,000 | 18,000 | - | - | Stock Option (right to buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 2,753 | 2,753 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 2,329 | 2,329 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 2,385 | 2,385 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 2,513 | 2,513 | - | - | Stock Option (Right to Buy) | |
| Macrogenics Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 2,121 | 2,121 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2021 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 1,575 | 1,575 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 8,878 | 8,878 | - | - | Stock Option (Right to Buy) |